GlassScriptPhysician profile
Brian A Glass
NPI 1265429146
$359.64
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.99 · 2020: $243 · 2021: $57.28.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $163.23 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.78 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.65 | 2019-2020 | |
| Bausch Health US, LLC | $16.17 | 2020 | |
| Therapeuticsmd, INC. | $12.64 | 2019 | |
| Daiichi Sankyo INC. | $11.17 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.